Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Sep
30
UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis
Sep
25
UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024
Sep
23
UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
Sep
23
Redefining Immunology Care: Our Pledge to Patients and the Healthcare Community
Sep
09
TK2d Awareness Day: The complexity of this rare, genetic mitochondrial disease and its impact on daily living can no longer be overlooked
